Abstract
A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiparazines under aerobic conditions is reported. Electron donating and sterically inducing aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an eco-friendly, cost-effective synthesis of these privileged structures.
Graphical abstract

N-Arylpiperazine moieties are prevalent in a vast amount of biologically-active compounds1 which display various pharmacological activities such as antiproliferative,2 antidepressant,3 anti-retroviral therapy of HIV,4 antimalarial,5 anti-Parkinsons,6 anti-anxiety7 and dopamine selective properties,8 and represent a potential gateway in combating substance abuse and dementia (Figure 1).9 In 2001 alone, the MDDR (MDL Drug Data Report) contained 2271 phenyl-piperazines, with 16 accounting for marketed drugs, while 23 were in phase II/III clinical trials across 18 therapeutic areas.10 Furthermore, aripiprazole (Ablify™) earned more than $7.9 billion in 2015, making it the second highest selling medication after holding the top spot in 2014.11 Therefore, synthesis and implementation of this privileged structure continues to play a vital role in drug development.
Figure 1.

Bioactive compounds containing cyclic and arylpiperazine scaffolds
Traditional synthesis of N-arylpiperazines requires the appropriate aniline precursor and bis(2-chloroethyl)amine hydrochloride.12 However, this synthetic method involves elevated temperatures, extended reaction times up to 24 hours, and is hampered by costly substituted anilines. Examples of microwave-assisted synthesis of N-arylpiperazines have been reported, but they too require substituted anilines13 and amine protecting groups.13b The Buchwald-Hartwig amination provides an attractive alternative via Pd-catalyzed C–N bond formation of aryl halides and amines.14 This catalysis has been applied to developing many bioactive compounds, and is currently the only reported methodology to facilitate a key step in the synthesis of Zykadia™, a drug for treating lung cancer.15 In 2008, Buchwald and co-workers reported 10 minute C–N cross coupling reactions with aryl chlorides using air- and moisture-stable Pd-precatalysts (Figure 2).16 To our knowledge, there have been no reports extending this 10 minute catalysis to a broad scope synthesis of N-arylpiperazines.
Figure 2.

Pd-precatalyst (A) and RuPhos (B)
Compared to other examples of Pd-catalyzed N-arylpiperazine synthesis,17 this methodology would not require anhydrous solvents, an inert atmosphere, and would be applicable to notoriously unreactive, electron-rich and sterically-congested aryl chlorides. In this report, we provide a 10 minute, benchtop synthesis demonstrating a wide scope with readily available aryl and N-heterocyclic chlorides. We also include eco-friendly examples of using piperazine as solvent, affording modest to good yields. This methodology will assist in the development of structurally diverse and sterically demanding, N-arylpiperazine compounds having a wide range of biological activity.
Initial efforts to optimize piperazine N-arylation were conducted with A and B following previously reported conditions with 1.5 equiv of piperazine.18 Although minimal aryl chloride was detected by LCMS after 10 min, a significant amount of the undesirable bis-arylated piperazine was observed. After exhausting other solvents and catalyst loading options, a 2:1 ratio of RuPhos/Pd2(dba)3 consistently provided moderate to high yields of the mono-arylated piperazine in 10 min. With optimized conditions in hand, a broad range of electron rich and deficient aryl chlorides were investigated (Table 1). Screening was limited to chloride substrates due to the economic value of these commercially-available reagents, compared to bromides and iodides. It is worth noting, no additional product formation was observed beyond the 10 min reaction time, unless otherwise noted. Milder base (Cs2CO3) was examined throughout the aryl chloride scope (Table 1), however lower yields were obtained compared to trials conducted with NaOtBu.
Table 1.
Piperazine Arylation Scope with Aryl Chloridesa
|
Investigation began with a series of anisoles, affording the desired products 2a-b in good yield; however, only a 66% yield was obtained with strongly deactivated 1c. The base sensitivity of the trifluoromethyl ether substituent on 1d required reducing the NaOtBu to 1.1 equiv to obtain a good yield of 2d. The reaction conditions were also applied to synthesize 2e, a key intermediate in the development of fluorinated D3 dopamine receptor ligands for positron emission tomography (PET) imaging studies,19 currently ongoing in our lab. Catalytic activity was impeded with sterically crowded 1g; however, a modest 62% isolated yield was still obtained in 10 min (2g).
Functional group compatibility was further explored to determine the tolerance of these substituents in the current reaction conditions. No product formation was observed with 1h, potentially due to coordination of the thiol substituent to the Pd-center, thus inhibiting catalytic activity. When using 1.1 equiv of the alkoxide base, nitro arene 2i was isolated in 86% yield, while other electron-poor aryl chlorides 1j-l provided excellent yields as well. The reaction conditions also provided access to chloro-containing N-arylpiperazines, motifs found in many antipsychotics,20 in good yield (2m-n). However, only a 37% yield of 2o was obtained due to side-product formation with the tri-chloro substrate 1o. Lastly, substrate 1p was investigated using 1.5 equiv of milder base Cs2CO3 to determine if non-aryl substrates were compatible to the illustrated reaction conditions. Indeed, the desired piperazine motif, present in Ciladopa, was afforded at a 75% yield (2p).
Nitrogen heterocycles were then investigated as these N-arylpiperazine scaffolds are commonly found in many medicinally-relevant compounds (Table 2).21 The high yields obtained with N-aryl chlorides matched previously reported trends of faster reductive elimination rates to form carbon–nitrogen bonds from Pd-complexes containing a heteroaromatic ring.22 For example, a yield of 94% was obtained with 3a and excellent yields of 4c-e were afforded with milder base Cs2CO3. The scope was expanded beyond six-membered heteroaromatic rings (3g-h), to include 2-chloroquinoline, affording the serotonin receptor agonist,3 Quipazine, in 93% yield (4h). Excellent yields were also obtained with benzothiazole and benzoxazole chlorides (3i-j), compounds with anti-cancer23 and antipsychotic24 properties, respectively. However, sluggish reactivity was observed with the five-membered heterocycle 2-chlorooxazole (3k), despite extending the reaction time beyond 10 min. Lower reactivity of five-membered heterocyclic electrophiles has previously been reported due to the electronic properties of certain ring positions which can be unfavorable for Pd-catalyzed coupling.25
Table 2.
Piperazine Arylation Scope with N-Aryl Chloridesa
|
Lastly, we wanted to investigate a solvent-free arylation of piperazine to demonstrate a “green” amination procedure (Table 3). While the Buchwald-Hartwig remains a dominant tool in C–N bond formation, reports illustrating solvent-free conditions are rare.26 Of those reports, only one example of unprotected piperazine has been examined, resulting in a high yield of the bis-arylated product.26g After optimizing piperazine equivalents with 2b, we were able to obtain modest yields of the desired mono-arylated products with selected chloride substrates. Although the afforded isolated yields are lower than those listed in Table 1 and 2, mainly due to bis-arylation, this method provides a more eco-friendly alternative by eliminating the need for potentially hazardous solvents.
Table 3.
Piperazine Arylation Conducted Neata
|
In conclusion, excellent yields of arylpiperazines were obtained in a one-pot, 10 min Buchwald-Hartwig amination, under aerobic conditions. Moderate to good yields were also obtained when conducting the reactions neat in piperazine, demonstrating an eco-friendly application to this catalysis. Finally, this procedure eliminates reaction times of many hours, and provides an efficient and vastly synthetically useful methodology in developing complex piperazine scaffolds of biological and pharmaceutical interest.
Supplementary Material
Acknowledgments
National Institute on Drug Abuse [(R01 DA29840-07 R.H. Mach) and (R01 DA23957-06 R.R. Luedtke)] is gratefully acknowledged for financial support.
Footnotes
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website.
Experimental procedure, NMR and mass spectral data of the isolated products (PDF)
References
- 1.Horton DA, Bourne GT, Smythe ML. Chem Rev. 2003;103:893–930. doi: 10.1021/cr020033s. [DOI] [PubMed] [Google Scholar]
- 2.(a) Berardi F, Abate C, Ferorelli S, de Robertis AF, Leopoldo M, Colabufo NA, Niso M, Perrone R. J Med Chem. 2008;51:7523–7531. doi: 10.1021/jm800965b. [DOI] [PubMed] [Google Scholar]; (b) Abate C, Niso M, Contino M, Colabufo NA, Ferorelli S, Perrone R, Berardi F. ChemMedChem. 2011;6:73–80. doi: 10.1002/cmdc.201000371. [DOI] [PubMed] [Google Scholar]; (c) Mao ZW, Zheng X, Lin YP, Hu CY, Wang XL, Wan CP, Rao GX. Bioorg Med Chem Lett. 2016;26:3421–3424. doi: 10.1016/j.bmcl.2016.06.055. [DOI] [PubMed] [Google Scholar]; (d) Chen H, Xu F, Liang X, Xu BB, Yang ZL, He XL, Huang BY, Yuan M. Bioorg Med Chem Lett. 2015;25:285–287. doi: 10.1016/j.bmcl.2014.11.049. [DOI] [PubMed] [Google Scholar]; (e) Mao Z, Zheng X, Qi Y, Zhang M, Huang Y, Wan C, Rao G. RSC Adv. 2016;6:7723–7727. [Google Scholar]
- 3.Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T. J Med Chem. 1998;41:728–741. doi: 10.1021/jm970645i. [DOI] [PubMed] [Google Scholar]
- 4.Romero DL, Morge RA, Genin MJ, Biles C, Busso M, Resnick L, Althaus IW, Reusser F, Thomas RC, Tarpley WG. J Med Chem. 1993;36:1505–1508. doi: 10.1021/jm00062a027. [DOI] [PubMed] [Google Scholar]
- 5.Mendoza A, Pérez-Silanes S, Quiliano M, Pabón A, Galiano S, González G, Garavito G, Zimic M, Vaisberg A, Aldana I, Monge A, Deharo E. Exp Parasitol. 2011;128:97–103. doi: 10.1016/j.exppara.2011.02.025. [DOI] [PubMed] [Google Scholar]
- 6.Koller WC, Fields JZ, Gordon JH, Perlow MJ. Neuropharmacol. 1986;25:973–979. doi: 10.1016/0028-3908(86)90190-5. [DOI] [PubMed] [Google Scholar]
- 7.Loane C, Politis M. Brain Res. 2012;1461:111–118. doi: 10.1016/j.brainres.2012.04.032. [DOI] [PubMed] [Google Scholar]
- 8.Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ. J Pharm Exp Ther. 1998;287:187–197. [PubMed] [Google Scholar]
- 9.(a) Sokoloff P, Foll BL, Perachon S, Bordet R, Ridray S, Schwartz JC. Neurotox Res. 2001;3:433–441. doi: 10.1007/BF03033202. [DOI] [PubMed] [Google Scholar]; (b) Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Nature. 1999;400:371–375. doi: 10.1038/22560. [DOI] [PubMed] [Google Scholar]; (c) Khaled MATM, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, Le Foll B. Int J Neuropsychopharmacol. 2010;13:181–190. doi: 10.1017/S1461145709991064. [DOI] [PubMed] [Google Scholar]; (d) Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH. J Med Chem. 2005;48:839–848. doi: 10.1021/jm049465g. [DOI] [PubMed] [Google Scholar]; (e) Garcia-Ladona FJ, Cox BF. CNS Drug Rev. 2003;9:141–158. doi: 10.1111/j.1527-3458.2003.tb00246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nilsson JW, Thorstensson F, Kvarnström I, Oprea T, Samuelsson B, Nilsson I. J Comb Chem. 2001;3:546–553. doi: 10.1021/cc010013o. [DOI] [PubMed] [Google Scholar]
- 11.Brown T. Top 10 Most Prescribed, Top-Selling Drugs. http://www.webmd.com/news/20150508/most-prescribed-top-selling-drugs, (accessed 08/23/2016)
- 12.(a) Mishani E, Dence CS, McCarthy TJ, Welch MJ. Tetrahedron Lett. 1996;37:319–322. [Google Scholar]; (b) Neuville L, Zhu J. Tetrahedron Lett. 1997;38:4091–4094. [Google Scholar]; (c) Ravilla L, Venkata Subba Naidu N, Nagarajan K. Tetrahedron Lett. 2015;56:4541–4544. [Google Scholar]
- 13.(a) Jaisinghani HG, Khadilkar BM. Tetrahedron Lett. 1997;38:6875–6876. [Google Scholar]; (b) Gao R, Canney DJ. J Org Chem. 2010;75:7451–7453. doi: 10.1021/jo101478c. [DOI] [PubMed] [Google Scholar]
- 14.(a) Yang BH, Buchwald SL. J Organomet Chem. 1999;576:125–146. [Google Scholar]; (b) Wolfe JP, Wagaw S, Marcoux JF, Buchwald SL. Acc Chem Res. 1998;31:805–818. [Google Scholar]; (c) Hartwig JF. Angew Chem, Int Ed. 1998;37:2046–2067. doi: 10.1002/(SICI)1521-3773(19980817)37:15<2046::AID-ANIE2046>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]; (d) Surry DS, Buchwald SL. Angew Chem, Int Ed. 2008;47:6338–6361. doi: 10.1002/anie.200800497. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Buchwald SL, Mauger C, Mignani G, Scholz U. Adv Synth Catal. 2006;348:23–39. [Google Scholar]; (f) Johansson Seechurn CCC, DeAngelis A, Colacot TJ. New Trends in Cross-Coupling: Theory and Applications, The Royal Society of Chemistry. 2015 [Google Scholar]
- 15.Flick AC, Ding HX, Leverett CA, Kyne RE, Jr, Liu KKC, Fink SJ, O’Donnell CJ. Bioorg Med Chem. 2016;24:1937–1980. doi: 10.1016/j.bmc.2016.03.004. [DOI] [PubMed] [Google Scholar]
- 16.Biscoe MR, Fors BP, Buchwald SL. J Am Chem Soc. 2008;130:6686–6687. doi: 10.1021/ja801137k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.(a) Nishiyama M, Yamamoto T, Koie Y. Tetrahedron Lett. 1998;39:617–620. [Google Scholar]; (b) Zhao SH, Miller AK, Berger J, Flippin LA. Tetrahedron Lett. 1996;37:4463–4466. [Google Scholar]; (c) Romero M, Harrak Y, Basset J, Ginet L, Constans P, Pujol MD. Tetrahedron. 2006;62:9010–9016. [Google Scholar]; (d) Urgaonkar S, Verkade JG. J Org Chem. 2004;69:9135–9142. doi: 10.1021/jo048716q. [DOI] [PubMed] [Google Scholar]; (e) Verma SK, Acharya BN, Kaushik MP. Org Biomol Chem. 2011;9:1324–1327. doi: 10.1039/c0ob00859a. [DOI] [PubMed] [Google Scholar]; (f) Hepperle M, Eckert J, Gala D, Shen L, Anderson Evans C, Goodman A. Tetrahedron Lett. 2002;43:3359–3363. [Google Scholar]
- 18.Fors BP, Buchwald SL. J Am Chem Soc. 2010;132:15914–15917. doi: 10.1021/ja108074t. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.(a) Tu Z, Li S, Cui J, Xu J, Taylor M, Ho D, Luedtke RR, Mach RH. J Med Chem. 2011;54:1555–1564. doi: 10.1021/jm101323b. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH. Bioorg Med Chem. 2005;13:77–87. doi: 10.1016/j.bmc.2004.09.054. [DOI] [PubMed] [Google Scholar]
- 20.(a) Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Neuropsychopharmacology. 1999;20:612–627. doi: 10.1016/S0893-133X(98)00099-2. [DOI] [PubMed] [Google Scholar]; (b) Cusack B, Nelson A, Richelson E. Psychopharmacology. 1994;114:559–565. doi: 10.1007/BF02244985. [DOI] [PubMed] [Google Scholar]
- 21.(a) Broekkamp CLE, Leysen D, Peeters BWMM, Pinder RM. J Med Chem. 1995;38:4615–4633. doi: 10.1021/jm00023a001. [DOI] [PubMed] [Google Scholar]; (b) Chen YL, Fang KC, Sheu JY, Hsu SL, Tzeng CC. J Med Chem. 2001;44:2374–2377. doi: 10.1021/jm0100335. [DOI] [PubMed] [Google Scholar]; (c) Hepperle M, Eckert J, Gala D. Tetrahedron Lett. 1999;40:5655–5659. [Google Scholar]; (d) Yan X, Mirzai B, Chackalamannil S, Czarniecki M, Wang S, Clemmons A, Ahn HS, Boykow GC. Bioorg Med Chem Lett. 1996;6:919–922. [Google Scholar]
- 22.Hartwig JF. Acc Chem Res. 2008;41:1534–1544. doi: 10.1021/ar800098p. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.(a) Ece G Enise, Ebru B, Irem D, Rengul C-A, Mine Y. Anticancer Agents Med Chem. 2015;15:382–389. [Google Scholar]; (b) Gurdal EE, Durmaz I, Cetin-Atalay R, Yarim M. J Enzyme Inhib Med Chem. 2015;30:649–654. doi: 10.3109/14756366.2014.959513. [DOI] [PubMed] [Google Scholar]
- 24.Huang L, Zhang W, Zhang X, Yin L, Chen B, Song J. Bioorg Med Chem Lett. 2015;25:5299–5305. doi: 10.1016/j.bmcl.2015.09.045. [DOI] [PubMed] [Google Scholar]
- 25.(a) Shen Q, Hartwig JF. J Am Chem Soc. 2007;129:7734–7735. doi: 10.1021/ja0722473. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Shen Q, Shekhar S, Stambuli JP, Hartwig JF. Angew Chem, Int Ed. 2005;44:1371–1375. doi: 10.1002/anie.200462629. [DOI] [PubMed] [Google Scholar]; (c) Su M, Buchwald SL. Angew Chem, Int Ed. 2012;51:4710–4713. doi: 10.1002/anie.201201244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.(a) Artamkina GA, Ermolina MV, Beletskaya IP. Mendeleev Commun. 2003;13:158–160. [Google Scholar]; (b) Basolo L, Bernasconi A, Broggini G, Gazzola S, Beccalli EM. Synthesis. 2013;45:3151–3156. [Google Scholar]; (c) Basolo L, Bernasconi A, Borsini E, Broggini G, Beccalli EM. ChemSusChem. 2011;4:1637–1642. doi: 10.1002/cssc.201100098. [DOI] [PubMed] [Google Scholar]; (d) Marelli E, Chartoire A, Le Duc G, Nolan SP. ChemCatChem. 2015;7:4021–4024. [Google Scholar]; (e) Chartoire A, Boreux A, Martin AR, Nolan SP. RSC Adv. 2013;3:3840–3843. [Google Scholar]; (f) Topchiy MA, Dzhevakov PB, Rubina MS, Morozov OS, Asachenko AF, Nechaev MS. Eur J Org Chem. 2016;2016:1908–1914. [Google Scholar]; (g) Topchiy MA, Asachenko AF, Nechaev MS. Eur J Org Chem. 2014;2014:3319–3322. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
